Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.43 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29392929 | 1.00 | MAOB (0.58) | MAOBMAOACYP11B2CYP11B1SMN1; SMN2 | |
| SCHEMBL3621421 | 0.85 | MAOB (0.47) | MAOBMAOASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL28793378 | 0.84 | MAOB (0.52) | MAOBMAOACYP11B2CYP11B1SMN1; SMN2 | |
| SCHEMBL17514843 | 0.83 | KMT2A (0.44) | MAOBMAOACYP11B2CYP11B1SMN1; SMN2 | |
| SCHEMBL27442149 | 0.83 | SMN1; SMN2 (0.48) | CYP11B2CYP11B1SMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL27841870 | 0.82 | MAOB (0.50) | MAOBMAOACYP11B2CYP11B1SMN1; SMN2 | |
| SCHEMBL18839711 | 0.81 | CYP11B2 (0.46) | MAOBMAOACYP11B2CYP11B1SMN1; SMN2 | |
| SCHEMBL392840 | 0.81 | SMN1; SMN2 (0.63) | CYP11B2SMN1; SMN2ALDH1A1KMT2ATSHR | |
| SCHEMBL645757 | 0.81 | ALDH1A1 (0.54) | MAOBCYP11B2CYP11B1SMN1; SMN2ALDH1A1 | |
| SCHEMBL22407068 | 0.81 | MAOB (0.68) | MAOBMAOACYP11B2CYP11B1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748839-A1 | POLYCYCLIC COMPOUND AND USE THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026087634-A1 | TREM2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4706757-A2 | 2-(((2,3-DIHYDROBENZO[B][1,4]DIOXAN-5-YL)PIPERIDIN-1-YL)METHYL)-1-((OXETAN-2-YL)METHYL)-1H-BENZO[D]IMIDAZOLE-6-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS GLP-1 MODULATORS FOR THE TREATMENT OF DIABETES | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2026-03-11 | — | — | EP | disclosed |
| EP-4209490-B1 | 2-(((2,3-DIHYDROBENZO[B][1,4]DIOXAN-5-YL)PIPERIDIN-1-YL)METHYL)-1-((OXETAN-2-YL)METHYL)-1H-BENZO[D]IMIDAZOLE-6-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS GLP-1 MODULATORS FOR THE TREATMENT OF DIABETES | JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-12522594-B2 | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2026-01-13 | — | — | US | disclosed |
| EP-4323354-B1 | 2-((4-((S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYLBENZO[D][1,3]DIOXOL-4-YL)PIPERIDIN-1-YL)METHYL)-1-(((S)-OXETAN-2-YL)METHYL)-1H-IMIDAZOLE DERIVATIVES AS ACTIVATORS OF THE GLP1 RECEPTOR FOR THE TREATMENT OF OBESITY | NOVARTIS AG (CH) | 2025-12-17 | — | — | EP | disclosed |
| EP-4660194-A1 | SALT AND CRYSTAL FORM OF CYCLOALKENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2025-12-10 | — | — | EP | disclosed |
| EP-4650353-A1 | 4-ALKOXY BENZIMIDAZOLE-6-CARBOXYLIC ACID DERIVATIVE SERVING AS GLP-1 RECEPTOR AGONIST | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2025-11-19 | — | — | EP | disclosed |
| US-12473279-B2 | Fused imidazole derivative, preparation method therefor, and medical use thereof | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-11-18 | — | — | US | disclosed |
| US-20040092402-A1 | Pyrimidine derivatives and herbicides containing the same | SUMITOMO CHEMICAL TAKEDA AGRO COMPANY, LIMITED (JP) | 2004-05-13 | — | — | US | disclosed |
| EP-1382603-A1 | NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
| EP-1333029-A1 | PYRIMIDINE DERIVATIVES AND HERBICIDES CONTAINING THE SAME | Sumitomo Chemical Takeda Agro Company, Limited (JP) | 2003-08-06 | — | — | EP | disclosed |
| EP-0769008-B1 | PYRAZOLE DERIVATIVES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2002-05-22 | — | — | EP | disclosed |
| EP-0735142-B1 | Process for producing (R)-styrene oxides | SUMIKA FINE CHEMICALS CO LTD (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-6083881-A | Pyrazole derivatives as herbicides | NOVARTIS CORPORATION (US) | 2000-07-04 | — | — | US | disclosed |
| US-5717116-A | TREATING A MIXTURE OF PHENYLHALOGENOMETHYLCARBINOLS WITH A LIPASE IN THE PRESENCE OF A CARBOXYLATE FOLLOWED BY CYCLIZATION WITH A BASE | SUMIKA FINE CHEMICALS COMPANY, LIMITED (JP) | 1998-02-10 | — | — | US | disclosed |
| EP-0769008-A1 | PYRAZOLE DERIVATIVES AS HERBICIDES | Novartis AG (CH) | 1997-04-23 | — | — | EP | disclosed |
| EP-0735142-A2 | Process for producing (R)-styrene oxides | SUMIKA FINE CHEMICAL COMPANY, LTD. (JP) | 1996-10-02 | — | — | EP | disclosed |
| WO-1996001254-A1 | PYRAZOLE DERIVATIVES AS HERBICIDES | CIBA-GEIGY AG (CH) | 1996-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092402-A1 | Pyrimidine derivatives and herbicides containing the same | DDX41, CBR3, DPYD | MAOB 2336/4885MAOA 2627/4885CYP11B2 2661/4885 |
| US-12473279-B2 | Fused imidazole derivative, preparation method therefor, and medical use thereof | GLP1R, GIPR, VIP | MAOB 2431/4885MAOA 2696/4885CYP11B2 85/4885 |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | GLP1R, GCKR, GPR119 | MAOB 2837/4885MAOA 2618/4885CYP11B2 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.